197 related articles for article (PubMed ID: 28715608)
1. Ticagrelor mitigates ischaemia-reperfusion induced vascular endothelial dysfunction in healthy young males - a randomized, single-blinded study.
Weisshaar S; Litschauer B; Eipeldauer M; Hobl EL; Wolzt M
Br J Clin Pharmacol; 2017 Dec; 83(12):2651-2660. PubMed ID: 28715608
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin combined with ticagrelor prevent ischemia-reperfusion induced vascular endothelial dysfunction in healthy young males - A randomized, placebo-controlled, double-blinded study.
Weisshaar S; Litschauer B; Kerbel T; Wolzt M
Int J Cardiol; 2018 Mar; 255():1-7. PubMed ID: 29288055
[TBL] [Abstract][Full Text] [Related]
3. Moderate, Short-Term, Local Hyperglycemia Attenuates Forearm Endothelium-Dependent Vasodilation After Transient Ischemia-Reperfusion in Human Volunteers.
Ebert TJ; Novalija J; Barney JA; Uhrich TD; Arain SR; Freed JK; Pagel PS
J Cardiothorac Vasc Anesth; 2017 Oct; 31(5):1649-1655. PubMed ID: 28284926
[TBL] [Abstract][Full Text] [Related]
4. Randomized Trial Comparing the Effects of Ticagrelor Versus Clopidogrel on Myocardial Perfusion in Patients With Coronary Artery Disease.
Pelletier-Galarneau M; Hunter CRRN; Ascah KJ; Beanlands RSB; Dwivedi G; deKemp RA; Chow BJW; Ruddy TD
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28465300
[TBL] [Abstract][Full Text] [Related]
5. Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects.
Guo LZ; Kim MH; Jin CD; Lee JY; Yi SJ; Park MK; Cho YR; Park TH
Platelets; 2015; 26(6):563-9. PubMed ID: 25275429
[TBL] [Abstract][Full Text] [Related]
6. The endothelin-1 receptor antagonist bosentan protects against ischaemia/reperfusion-induced endothelial dysfunction in humans.
Böhm F; Settergren M; Gonon AT; Pernow J
Clin Sci (Lond); 2005 Apr; 108(4):357-63. PubMed ID: 15610070
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Clopidogrel on the Response to Ischemia Reperfusion.
Kwong W; Parker JD
J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):368-373. PubMed ID: 28587582
[TBL] [Abstract][Full Text] [Related]
8. Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome.
Caiazzo G; De Rosa S; Torella D; Spaccarotella C; Mongiardo A; Giampà S; Micieli M; Palella E; Gulletta E; Indolfi C
Circ Cardiovasc Interv; 2014 Feb; 7(1):104-12. PubMed ID: 24449597
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.
Butler K; Teng R
Br J Clin Pharmacol; 2010 Jul; 70(1):65-77. PubMed ID: 20642549
[TBL] [Abstract][Full Text] [Related]
10. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
[TBL] [Abstract][Full Text] [Related]
11. Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus.
Clavijo LC; Maya J; Carlson G; Angiolillo DJ; Teng R; Caplan R; Price MJ
Cardiovasc Revasc Med; 2015 Dec; 16(8):450-4. PubMed ID: 26440227
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease.
Zafar MU; Baber U; Smith DA; Sartori S; Contreras J; Rey-Mendoza J; Linares-Koloffon CA; Escolar G; Mehran R; Fuster V; Badimon JJ
Thromb Haemost; 2017 Oct; 117(10):1981-1988. PubMed ID: 28837213
[TBL] [Abstract][Full Text] [Related]
13. Randomized Comparison of Oral P2Y
Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
[TBL] [Abstract][Full Text] [Related]
14. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study.
Jin C; Kim MH; Bang J; Serebruany V
Cardiology; 2017; 138(4):201-206. PubMed ID: 28810251
[TBL] [Abstract][Full Text] [Related]
15. Intra-arterial vitamin C prevents endothelial dysfunction caused by ischemia-reperfusion.
Pleiner J; Schaller G; Mittermayer F; Marsik C; MacAllister RJ; Kapiotis S; Ziegler S; Ferlitsch A; Wolzt M
Atherosclerosis; 2008 Mar; 197(1):383-91. PubMed ID: 17645881
[TBL] [Abstract][Full Text] [Related]
16. Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor.
Barbieri L; Verdoia M; Pergolini P; Nardin M; Rolla R; Marino P; Bellomo G; Suryapranata H; De Luca G;
Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):352-8. PubMed ID: 26857781
[TBL] [Abstract][Full Text] [Related]
17. Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial.
Li P; Gu Y; Yang Y; Chen L; Liu J; Gao L; Qin Y; Cai Q; Zhao X; Wang Z; Ma L
Sci Rep; 2016 Aug; 6():31838. PubMed ID: 27554803
[TBL] [Abstract][Full Text] [Related]
18. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Antiplatelet Effects of Once and Twice Daily Low-Dose Ticagrelor and Clopidogrel After Percutaneous Coronary Intervention.
Choi KN; Jin HY; Shin HC; Park YA; Seo JS; Jang JS; Yang TH; Kim DK; Kim DS
Am J Cardiol; 2017 Jul; 120(2):201-206. PubMed ID: 28554486
[TBL] [Abstract][Full Text] [Related]
20. Postconditioning protects against human endothelial ischaemia-reperfusion injury via subtype-specific KATP channel activation and is mimicked by inhibition of the mitochondrial permeability transition pore.
Okorie MI; Bhavsar DD; Ridout D; Charakida M; Deanfield JE; Loukogeorgakis SP; MacAllister RJ
Eur Heart J; 2011 May; 32(10):1266-74. PubMed ID: 21362704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
